<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509609</url>
  </required_header>
  <id_info>
    <org_study_id>000000</org_study_id>
    <nct_id>NCT04509609</nct_id>
  </id_info>
  <brief_title>Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E</brief_title>
  <acronym>NeuroLGMD2E</acronym>
  <official_title>Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective observational study that will enable us to collect retrospective data from&#xD;
      the clinical records of LGMD 2E patients in order to highlight any possible correlation&#xD;
      between:&#xD;
&#xD;
        -  clinical variables and patient age,&#xD;
&#xD;
        -  clinical variables and other clinical variables,&#xD;
&#xD;
        -  clinical variables and clinical outcomes. The study will help to define the natural&#xD;
           history of this rare disease and to ameliorate the management of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective observational study. Retrospective data from clinical charts of patients&#xD;
      affected by LGMD 2E will be collected after the subscription of informed consent.Data&#xD;
      considered will include any clinical variable measured, both objective and subjective. All&#xD;
      data obtained will be anonimized before any treatment. Data will be grouped according to the&#xD;
      age of the patient, in order to have more data for each age and to gain a trustable&#xD;
      description of the disease progression. The possible correlation of each variable to age, to&#xD;
      other variables and to objective clinical outcomes will be studied. Clinical outcomes&#xD;
      considered will include age of loss of deambulation, age of introduction of respiratory&#xD;
      assist, age of introduction of cardiological therapy. Data collected will also be divided in&#xD;
      two groups according to different genetic diagnosis in order to evaluate phenotipical&#xD;
      differences of genotypical clesses. First group will count all patient with the truncating&#xD;
      mutation c.377_384duplCAGTAGGA in exon 3, both in heterozigosis and in homozigosis Second&#xD;
      group will include all the other patients.&#xD;
&#xD;
      Both on the global data collection and on data divided according to genotype, statistical&#xD;
      analysis will be performed. Those analysis will study linear regression both with the&#xD;
      univariate, bivariate and multivariate model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Natural history</measure>
    <time_frame>december 2020</time_frame>
    <description>The clinical progression of the disease will be studied considering for each clinical variable its evolution according to patients' ages. This both in overall cohort and in genetic subgroups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Guidelines</measure>
    <time_frame>december 2020</time_frame>
    <description>The collection of clinical variables describing the progression of the disease will enable a better clinical management of these patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">33</enrollment>
  <condition>LGMD2E</condition>
  <arm_group>
    <arm_group_label>LGMD 2E with a genetic diagnosis</arm_group_label>
    <description>Any patient affected by LGMD 2E with a genetic diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exon 3 truncating mutation</intervention_name>
    <description>Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis</description>
    <arm_group_label>LGMD 2E with a genetic diagnosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Any other mutation in SGBC gene</intervention_name>
    <description>Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis</description>
    <arm_group_label>LGMD 2E with a genetic diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient affected by LGMD 2E that have received a genetical confirm of the diagnosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gene based diagnosis of LGMD 2E&#xD;
&#xD;
          -  Subscription of informed consent when applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lacking gene based diagnosis of LGMD 2E&#xD;
&#xD;
          -  Lacking subscription of informed consent when applicable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvan Torrente</last_name>
      <phone>+39 025503874</phone>
      <email>yvan.torrente@policlinico.mi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>under EU GDPR, this would be extremely complex</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04509609/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04509609/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

